Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 (TYK2) Inhibitor, in Patients with Moderate to Severe Scalp Psoriasis: The Association Between Patient-Reported and Clinician-Reported Outcomes at Week 16 in a Phase 3b/4 Multicenter, Randomized, Double-blinded, Placebo-controlled Study (PSORIATYK SCALP). J of Skin [Internet]. 2025 Mar. 17 [cited 2025 Jun. 25];9(2):s528. Available from: https://skin.dermsquared.com/skin/article/view/3310